Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Operating Leases (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Operating Leases for 4 consecutive years, with $2.6 million as the latest value for Q4 2025.

  • For Q4 2025, Operating Leases rose 1.04% year-over-year to $2.6 million; the TTM value through Dec 2025 reached $2.6 million, up 1.04%, while the annual FY2025 figure was $2.6 million, 1.04% up from the prior year.
  • Operating Leases was $2.6 million for Q4 2025 at Day One Biopharmaceuticals, down from $2.7 million in the prior quarter.
  • The five-year high for Operating Leases was $2.9 million in Q1 2025, with the low at $77000.0 in Q3 2023.
  • Historically, Operating Leases has averaged $1.5 million across 4 years, with a median of $1.6 million in 2022.
  • The largest annual shift saw Operating Leases crashed 85.02% in 2023 before it soared 3196.1% in 2024.
  • Over 4 years, Operating Leases stood at $408000.0 in 2022, then plummeted by 81.13% to $77000.0 in 2023, then surged by 3266.23% to $2.6 million in 2024, then grew by 1.04% to $2.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $2.6 million in Q4 2025, $2.7 million in Q3 2025, and $2.8 million in Q2 2025.